Results of a prospective multicenter trial of CTAG thoracic endograft William D. Jordan, MD, Joshua Rovin, MD, Sina Moainie, MD, Joseph Bavaria, MD, Richard Cambria, MD, Mark Fillinger, MD, William McMillan, MD, Jon S. Matsumura, MD Journal of Vascular Surgery Volume 61, Issue 3, Pages 589-595 (March 2015) DOI: 10.1016/j.jvs.2014.09.033 Copyright © 2015 Terms and Conditions
Fig 1 The Conformable GORE TAG (CTAG) composite device. Image courtesy of W. L. Gore & Associates Inc. Journal of Vascular Surgery 2015 61, 589-595DOI: (10.1016/j.jvs.2014.09.033) Copyright © 2015 Terms and Conditions
Fig 2 Aneurysm-related mortality. The range bars show the standard deviation. Journal of Vascular Surgery 2015 61, 589-595DOI: (10.1016/j.jvs.2014.09.033) Copyright © 2015 Terms and Conditions
Fig 3 All-cause mortality. The range bars show the standard deviation. Journal of Vascular Surgery 2015 61, 589-595DOI: (10.1016/j.jvs.2014.09.033) Copyright © 2015 Terms and Conditions